<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; expand</title>
	<atom:link href="http://www.tapanray.in/tag/expand/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Expand Market Share Unleashing Digital Health Potential For All</title>
		<link>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=expand-market-share-unleashing-digital-health-potential-for-all</link>
		<comments>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/#comments</comments>
		<pubDate>Mon, 15 Nov 2021 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10609</guid>
		<description><![CDATA[“Advancement in digital health is currently restricted mainly to economically and socially privileged populations. Those having access, resources and basic digital skills, are reaping disproportionate benefits from the technology and other associated infrastructure available for this purpose. Unfortunately, underserved population, &#8230; <a href="http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India To Expand NLEM 2011: A Step In The Right Direction</title>
		<link>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-to-expand-nlem-2011-a-step-in-the-right-direction</link>
		<comments>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/#comments</comments>
		<pubDate>Mon, 11 May 2015 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Expansion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lok Sabha]]></category>
		<category><![CDATA[Margaret Chan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[union budget]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6591</guid>
		<description><![CDATA[Responding to growing discontentment on the flawed National List of Essential Medicines 2011 (NLEM 2011) and equally vociferous demand for its urgent rectification, on May 5, 2015, in a written reply to the Lower House of Indian Parliament (Lok Sabha) &#8230; <a href="http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Herceptin Biosimilar Expands Drug Access to Breast Cancer Patients in India</title>
		<link>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india</link>
		<comments>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/#comments</comments>
		<pubDate>Fri, 24 Jan 2014 13:37:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[herclon]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4908</guid>
		<description><![CDATA[Come February 2014, much to the relief of more than 145,000 patients diagnosed with breast cancer in India, Herceptin of Roche, a critical drug for the treatment of the dreaded disease, will face competition, for the first time, from a &#8230; <a href="http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
